Growth • Jazz Pharmaceuticals
JAZZ
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
13,5%
CAGR Revenue 5Y
Revenue Compound Annual Growth Rate in the last 5 years.
2,5%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
1,4%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
-1%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
-3,4%
CAGR Normalized EPS 5Y
Normalized Earnings Per Share Compound Annual Growth Rate in the last 5 years.
12,4%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!